Conclusions: Nephropathy, obesity, and dyslipidemia are known to correlate to hyperuricemia and gout. Reciprocally hyperuricemia and gout may lead to development of comorbidities, i.e. hypertension, CVD, and nephropathy. Almost half the patients in this study were obese emphasizing the correlation between hyperuricemia and gout and obesity. Weight reduction is beneficial for control of hyperuricemia and gout, and is an important lifestyle factor that may be addressed in the treatment of hyperuricemia. Metabolic Syndrome is characterized by abdominal obesity and at least two of the following criteria: hypertension, diabetes, hypertriglyceridemia, and low blood levels of high-density-lipoprotein. Metabolic Syndrome is associated with a two-fold risk of CVD and was present in 72% of the gout patients. High homocysteine levels are correlated to endothelial dysfunction and increased risk of CVD. In this study the majority of patients had levels of homocysteine in the upper normal range, and a quarter had hyper-homocysteinemia. Elevated homocysteine has previously been reported in gout correlated to impaired renal function, but hyper-homocysteinmia can also be induced by low blood levels of cobalamin, which was present in 16%, and low levels of folate, which was found in 26%. In addition, low folate has been associated with endothelial dysfunction and CVD independently of homocysteine. Low levels of 25(OH)-vitamin D3 were observed in nearly half of the gout patients and deficiency were found in 19%. Obesity is known to be associated with low levels of vitamin D. Negative correlation between uric acid and Vitamin D has though been reported after correction for weight. Uric acid suppresses 1-alpha hydroxylase leading to low levels of 1,25(OH)2-vitamin D3 which is correlated to dyslipidemia and Metabolic Syndrome. Urate Lowering Therapy has been shown to counteract suppression of 1-alpha hydroxylase. Due to the increased risk of CVD and death associated with gout and the high prevalence of comorbidities and CVD risk factors in gout patients -comprehensive evaluation, information, and treatment of reversible co-morbidities and risk factors is recommended to be a part of the clinical management of gout. Background: Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved for treatment of patients with chronic refractory gout. It profoundly decreases serum uric acid (UA) and resolves tophi, but the quality of the clinical benefit in patients achieving long-term UA lowering has not been assessed. Objectives: To assess the clinical benefit of long-term UA-lowering with pegloticase in patients with gout.
AB0892 PROGRESSIVE CLINICAL BENEFIT IN CHRONIC REFRACTORY GOUT PATIENTS ACHIEVING A PERSISTENT URATE LOWERING EFFECT FROM PEGLOTICASE TREATMENT
Background: Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved for treatment of patients with chronic refractory gout. It profoundly decreases serum uric acid (UA) and resolves tophi, but the quality of the clinical benefit in patients achieving long-term UA lowering has not been assessed.
Objectives:
To assess the clinical benefit of long-term UA-lowering with pegloticase in patients with gout.
Methods: This analysis used results from two randomized controlled trials (RCTs) of 6-months duration and the 2-year open-label extension (OLE) of these studies. 1,2 Efficacy was assessed in responders to the approved treatment regimen (8 mg pegloticase every 2 weeks [q2w]) in the RCTs (i.e., patients with plasma UA <6.0 mg/dL for ≥80% of the assessments around the 3 and 6 month time periods.) Clinical assessments included serum UA, frequency of gout flares, Patient Global Assessment (PGA), tender and swollen joints (TJC and SJC), pain measured with a 100-mm visual analog scale (VAS), Health Assessment Questionnaire Disability Index, bodily pain and the Arthritis-Specific Health Index from the Medical Outcomes Study Short Form 36 item, and reduction of target tophi. Results: 33 patients who responded to pegloticase in the RCTs were followed throughout the OLE. Of these, 20 received 8 mg pegloticase q2w and 13 q4w. Both groups maintained markedly decreased serum UA levels during the OLE. Results for patients who received pegloticase q2w indicated significant improvements between RCT baseline and the final OLE evaluation for serum UA (P<0.0001), PGA (P=0.02), TJC (P=0.04), SJC (P=0.01), and pain VAS (P=0.01); 61.5% of patients in this group had complete target tophus resolution (P<0.0001). Results for those treated q4w indicated significant improvements between RCT baseline and the final OLE evaluation for serum UA (P<0.001), PGA (P=0.004), TJC (P=0.004), SJC (P=0.012), and pain VAS (P=0.01); 100% of patients in this group had complete tophus resolution (P<0.001). After an initial increase in gout flares during the initial 3 months of the RCT, there was a persistent decrease throughout the OLE. Maximal target tophus reduction was observed after 13-25 weeks of the OLE. Two of 20 (10%) patients receiving pegloticase q2w and 4 of 13 (31%) treated q4w lost the persistent UA-lowering effect during the OLE. Conclusions: There were significant sustained clinical benefits with long-term pegloticase treatment in patients with chronic refractory gout achieving a UA lowering effect during the first 6 months of therapy. Significant decreases in TJC, SJC, and pain were noted along with significant improvements in PGA, suppression of gout flares, and resolution of tophi. In most patients, maximal benefit was noted after 6-12 months of pegloticase therapy, with many patients meeting newly proposed criteria for gout remission. 
